Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9069996 | 0.91 | CHRM2 (0.55) | CHRM2CARM1PRMT6PRMT8CYP2C9 | |
| SCHEMBL902505 | 0.90 | — | — | |
| SCHEMBL11434663 | 0.90 | CHRM2 (0.68) | CHRM2CARM1PRMT6PRMT8CYP2C9 | |
| SCHEMBL15075 | 0.89 | — | — | |
| SCHEMBL19941957 | 0.88 | CHRM2 (0.65) | CHRM2CARM1PRMT6PRMT8CYP2C9 | |
| SCHEMBL4285948 | 0.88 | CHRM2 (0.83) | CHRM2CARM1PRMT6PRMT8CA12 | |
| SCHEMBL10045281 | 0.87 | CHRM2 (0.72) | CHRM2CYP2C9CYP2C19CA12CA2 | |
| SCHEMBL13703903 | 0.87 | CHRM2 (0.72) | CHRM2CYP2C9CYP2C19CA12CA2 | |
| SCHEMBL1262347 | 0.86 | CHRM2 (0.53) | CHRM2CARM1PRMT6PRMT8CYP2C9 | |
| SCHEMBL31034365 | 0.86 | CHRM2 (0.53) | CHRM2CARM1PRMT6PRMT8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151735-A1 | IONIZABLE LIPIDS FOR DRUG DELIVERY | CARNEGIE MELLON UNIVERSITY (US) | 2025-07-17 | — | — | WO | claimed |
| JP-2006502081-A | — | — | 2006-01-19 | — | — | JP | claimed |
| US-20050085555-A1 | Composition, synthesis and therapeutic applications of polyamines | MURPHY, MICHAEL A. | 2005-04-21 | — | — | US | claimed |
| EP-1465611-A2 | COMPOSITION, SYNTHESIS AND THERAPEUTIC APPLICATIONS OF POLYAMINES | Murphy, Michael A. (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2003051348-A2 | COMPOSITION, SYNTHESIS AND THERAPEUTIC APPLICATIONS OF POLYAMINES | MURPHY MICHAEL A (US) | 2003-06-26 | — | — | WO | claimed |
| US-20250375392-A1 | Branched Tail Lipids and Uses Thereof | UNIV CARNEGIE MELLON (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250236585-A1 | SPLEEN-TARGETED IONIZABLE LIPID COMPOUND, COMPOSITION COMPRISING SAME AND USE THEREOF | BEIJING CARRIUS BIO LTD. (CN) | 2025-07-24 | — | — | US | disclosed |
| WO-2025151735-A1 | IONIZABLE LIPIDS FOR DRUG DELIVERY | CARNEGIE MELLON UNIVERSITY (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250179015-A1 | DEGRADABLE LIPID FOR ACTIVE MOLECULE DELIVERY AND LIPID NANOPARTICLE THEREOF | BEIJING CARRIUS BIO LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| WO-2025066954-A1 | DEGRADABLE LIPOSOME FOR ACTIVE MOLECULE DELIVERY, AND LIPID NANOPARTICLE THEREOF | 北京云溪智响生物科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-118026900-B | Spleen-targeted ionizable lipid compounds, compositions comprising same and uses | 北京云溪智响生物科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-117865863-B | Degradable liposome for active molecule delivery and lipid nanoparticle thereof | 北京云溪智响生物科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-6946472-B2 | Polycyclic compounds exhibiting anti-tumor activities | HOFFMAN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2005054236-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS S.L. (ES) | 2005-06-16 | — | — | WO | disclosed |
| US-20050085555-A1 | Composition, synthesis and therapeutic applications of polyamines | MURPHY, MICHAEL A. | 2005-04-21 | — | — | US | disclosed |
| EP-1465611-A2 | COMPOSITION, SYNTHESIS AND THERAPEUTIC APPLICATIONS OF POLYAMINES | Murphy, Michael A. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-11 | — | — | US | disclosed |
| WO-2003093265-A1 | DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003051348-A2 | COMPOSITION, SYNTHESIS AND THERAPEUTIC APPLICATIONS OF POLYAMINES | MURPHY MICHAEL A (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030013772-A1 | Composition, synthesis and therapeutic applications of polyamines | MURPHY, MICHAEL A. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013772-A1 | Composition, synthesis and therapeutic applications of polyamines | TXN2, PYCR1, SQOR | CHRM2 195/4885CARM1 776/4885PRMT6 266/4885 |
| US-20250236585-A1 | SPLEEN-TARGETED IONIZABLE LIPID COMPOUND, COMPOSITION COMPRISING SAME AND USE THEREOF | SGPL1, SGMS2, SGMS1 | CHRM2 4844/4885CARM1 2670/4885PRMT6 3830/4885 |
| US-20050085555-A1 | Composition, synthesis and therapeutic applications of polyamines | PRDX5, PINK1, ARG2 | CHRM2 549/4885CARM1 976/4885PRMT6 346/4885 |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | RB1, CCNA1, ACIN1 | CHRM2 4593/4885CARM1 206/4885PRMT6 474/4885 |
| US-20250179015-A1 | DEGRADABLE LIPID FOR ACTIVE MOLECULE DELIVERY AND LIPID NANOPARTICLE THEREOF | LNPEP, CETP, PLTP | CHRM2 4867/4885CARM1 2106/4885PRMT6 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.